Bei Shan

Founder and CEO at BioFront Therapeutics
  • Claim this Profile
Contact Information
Location
Beijing, CN

Topline Score

Bio

Generated by
Topline AI

0

/5.0
/ Based on 0 ratings
  • (0)
  • (0)
  • (0)
  • (0)
  • (0)

Filter reviews by:

No reviews to display There are currently no reviews available.

0

/5.0
/ Based on 0 ratings
  • (0)
  • (0)
  • (0)
  • (0)
  • (0)

Filter reviews by:

No reviews to display There are currently no reviews available.
You need to have a working account to view this content. Click here to join now

Experience

    • China
    • Pharmaceutical Manufacturing
    • 1 - 100 Employee
    • Founder and CEO
      • May 2019 - 4 years 8 months

      Beijing, China With a strong team of biopharmaceutical veterans and adequate funding, BioFront aims to identify disease drivers and develop first-in-class therapeutics through profit-sharing partnerships with academic investigators.

    • United States
    • Pharmaceutical Manufacturing
    • 700 & Above Employee
    • Executive Research Director, Lilly China Innovation and Partnerships
      • Jan 2018 - May 2019

      Shanghai, China

    • Head of Biology, Lilly China Research & Development Center
      • Sep 2011 - Dec 2017

      Shanghai, China

    • United States
    • Biotechnology Research
    • 700 & Above Employee
    • Scientific Executive Director
      • Sep 2005 - Aug 2011

      San Francisco Bay Area

    • Research Director
      • Aug 2004 - Sep 2005

      San Francisco Bay Area Tularik was acquired by Amgen in Aug 2004

    • Biotechnology Research
    • 1 - 100 Employee
    • Research Director
      • Jun 2000 - Aug 2004

      San Francisco Bay Area

    • Scientist, Principal Investigator
      • Jun 1995 - Jun 2000

      San Francisco Bay Area

Education

  • UCSD
    Postdoc
    1990 - 1991
  • UT Health Science Center at San Antonio
    Postdoc
    1991 - 1995
  • SUNY Downstate Medical Center
    Ph.D., Molecular Biology
    1983 - 1990
  • ECNU

Community

You need to have a working account to view this content. Click here to join now